SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

Impact · against what's priced in

The long-term IBD data for SKYRIZI and RINVOQ are positive but largely confirm the growth trajectories the market already expects from these two pillars. While the data supports the required revenue CAGR, it does not introduce a new catalyst that justifies the higher bull-case valuations currently rejected by the market.

ABBV+0.10

Already priced in

The price assumes

SKYRIZI and RINVOQ replacing HUMIRA's lost revenue